Biotech Startups

QuTEM provides electron microscopy analytics with proprietary software (Gridsee) for quality control of gene therapies, enabling manufacturers to ensure safety and consistency at regulatory and production scale. The company serves pharmaceutical and gene therapy manufacturers navigating commercialization and regulatory approval requirements.

1 investor

Kawa Project produces a cocoa powder alternative derived from processed coffee waste using food science and manufacturing techniques. The company serves the food and beverage industry seeking sustainable ingredients.

1 investor

KBG (Kromberg) develops, manufactures, and sells vitamin and mineral premixes, dietary supplements, and raw materials. It supplies synthetic, biological, and natural substances to the food, cosmetic, and pharmaceutical industries.

1 investor

KCAS Bio is a bioanalytical contract research organization (CRO) providing preclinical and clinical bioanalysis, biomarker, immunogenicity, flow cytometry, and sample management services to drug development sponsors. It operates lab facilities across the US and Europe with a strategic alliance in Australia, serving pharmaceutical, biologics, and veterinary health developers.

1 investor

KCAT Enzymatic is an enzyme and protein engineering group that develops algorithms and hardware using quantum mechanics and AI to model enzyme structure-function relationships and engineer industrially viable biocatalysts. It operates a computational lab and a biotech lab for high-throughput screening and enzyme production for industrial applications.

1 investor

Kelsey is an AI-powered clinical trial placement platform that searches hundreds of thousands of institution and investigator records to recommend trial sites, resolving queries through the NIH/National Library of Medicine's MeSH disease taxonomy. It also offers a ClinOps service that handles site identification, feasibility, budget negotiation, and contracted site startup for sponsors and research teams.

1 investor

Kemin develops and manufactures specialty ingredients across areas including human and animal nutrition, pet food, plant science, and health applications. The company operates globally, serving customers in more than 120 countries with over 500 specialty ingredients.

1 investor

1 investor

kēpos produces a microbiome health supplement formulated to support digestive health, developed in partnership with the University of Chicago. The product targets individuals seeking science-backed digestive wellness solutions.

1 investor

Kerafast is an online marketplace that distributes laboratory reagents and research materials sourced from academic and research institutions, making individual scientists' unique reagents available to the global research community. It serves life science researchers and connects laboratories that produce specialized reagents with those seeking them.

1 investor

Arkin Capital is a multi-asset investment manager overseeing more than $2.5 billion across venture capital, private equity, hedge funds, and real estate, with investment arms covering health, equity, tech, and property. It invests in biotech, digital health, technology startups, and global real estate, with activity spanning Israel, North America, and Europe.

1 investor

Kestrel Therapeutics develops targeted cancer therapies focused on inhibiting KRAS mutations across all tumor types using structure-based drug design. The company is building oncology treatments for cancer patients with KRAS-mutated tumors.

1 investor

KeystoneBio provides an underwriting engine that automates analysis of clinical trials, deals, and competitive data for biotech investors. The platform is designed for private and public market investors to conduct research, diligence, and portfolio management.

1 investor

Khanda is a biotech company builder that translates validated and emerging biological insights into new biotechnology companies focused on orthogonal, combination-based therapeutic approaches. It develops medicines aimed at chronic diseases, with a team of drug developers, scientists, and company builders.

1 investor

Khumbu builds an AI platform for drug discovery, described as a "World Model for Molecular Biology" that combines quantum mechanics, structural biology, and machine learning. The company also runs its own internal therapeutic programs.

1 investor

KIDEMIS produces mycelium-based protein ingredients for aquafeed, made from upcycled agricultural sidestreams, to replace wild fish and shrimp meal in the aquaculture industry. Its products aim to make aquaculture more sustainable and reduce pressure on wild fish stocks and agricultural land.

1 investor

KiinOS is a scientific intelligence platform that connects experimental results, generates insights, and supports planning and execution of scientific work. It offers flexible integrations for various research use cases and serves scientific and research organizations.

1 investor

KIJI Tx develops gene-engineered iPSC-derived MSC cell therapies for treating a broad range of inflammatory diseases, with a lead product using IL10 and CXCR4 transduction. The company works in collaboration with research institutions including CIBER, Fundación Jiménez Díaz, and CIEMAT.

1 investor

Kilele Health develops biosensing medical devices for patient monitoring and diagnostics. The company combines advanced biosensing technology with expertise in medtech development and commercialization to serve healthcare providers and patients.

1 investor

Kilobaser develops tabletop DNA and RNA synthesizers designed for laboratory professionals to produce custom oligonucleotides on demand. The company targets life science researchers and lab professionals seeking independent access to genetic material synthesis.

1 investor

Kimia Farma is an Indonesian pharmaceutical company operating across the value chain, including raw material and drug manufacturing (ethical, generic, OTC, and herbal medicines and medical devices), national pharmaceutical distribution, retail pharmacy, and health clinics and laboratories. It runs over 1,300 retail outlets, around 400 health clinics, and a distribution network reaching more than 30,000 channels in Indonesia.

1 investor

Kindling Bio develops targeted cancer gene therapy for children that uses the immune system to fight a range of tumors. The company focuses on pediatric oncology, aiming to replace toxic adult-designed therapies with treatments tailored to children's biology.

1 investor

Kiniksa is a global biopharmaceutical company that discovers and develops novel therapies for patients with unmet medical needs, with a focus on cardiovascular diseases and related conditions. The company has an FDA-approved therapy and multiple clinical-stage assets in its pipeline.

1 investor

Kinimmune develops localized immunotherapies that activate the immune system at the site of solid tumors. Its lead program, KIN-112, pairs a proprietary peptide with a TLR agonist to concentrate treatment within the tumor and mobilize immune cells against cancer.

1 investor